Decrease in mammary tumour incidence in virgin C3H mice given interferon only while suckling. by Toliou, T. R. et al.
Br. J. ofCancer (1983), 47, 803-807
Decrease in mammary tumour incidence in virgin C3H mice
given interferon only while suckling
T.R. Toliou, C.G. Gabrielides, N. Papakyriazis & J. Taylor-Papadimitriou
Theagenion Cancer Institute, Serron 2, Thessaloniki, Greece.
Summary A high proportion of females of the C3H strain of mice develop tumours of the mammary gland
which are caused by mouse mammary tumour virus (MMTV) transmitted through the milk. We have
examined whether administration of mouse interferon (IFN) to nursing mothers and/or their suckling
offspring only during the period of nursing, can affect the incidence of tumours developing in these animals.
In two separate experiments, animals receiving IFN by direct injection while suckling, and remaining virgin
showed a marked and statistically significant decrease in tumour incidence. Mice receiving the same or a
tenfold higher dose of IFN while lactating showed no such reduction in tumour incidence, even if they had
also received IFN while suckling. The results suggest that IFN can affect the initial establishment of the
MMTV infection in suckling mice sufficiently to delay tumour development provided the animals are not
exposed to the hormonal stimulus of pregnancy and lactation.
Interferon (IFN) has been shown to be effective in
inhibiting the development of a wide range of
animal tumours (Gresser & Tovey, 1978) and is
now being considered as an anti-cancer agent in
man (Strander, 1977). Among the tumours whose
development has been shown to be affected by IFN
are the spontaneous mammary tumours which
develop in a high proportion of the females in some
strains of mice, and which are known to be induced
by a virus (Came & Moore, 1972). In the C3H and
RIII strains of mouse, the mouse mammary tumour
virus (MMTV) is known to be passed to the
offspring via the milk, (Symers, 1936) and several
copies of the provirus become integrated into the
epithelial cells of the mammary gland, the specific
target organ, where the virus replicates (for review
see Hilgers & Bentvelzer, 1980).
Where IFN has been shown to inhibit the
development of mouse mammary tumours induced
by a milk borne virus, it has been administered
daily over several months (Came & Moore, 1972).
There are, however, two critical periods in the life
cycle of the mouse, namely when the MMTV
infection is becoming established in the suckling
mouse and when the virus is replicating in the
functioning mammary gland at pregnancy and
lactation. In this paper, we have asked the question
as to whether it is possible to reduce the incidence
of spontaneous mammary tumours in C3H mice by
administering IFN during these two critical periods,
i.e. during suckling and/or while nursing. Our
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results indicate that IFN administered to suckling
mice can reduce the incidence of tumours in the
mice provided they remain virgin. However,
administration of IFN during lactation, when viral
replication would be expected to be maximal, has
no protective effect, even when the mice had also
been given IFN while suckling.
Materials and methods
Interferon preparations
The production of mouse IFN was induced in
C243C cells with NDV virus (3p.f.u./cell) (Oie et al.,
1972). The virus was inactivated by acidifying the
solution to pH 2 and the IFN concentrated and
partially purified by adsorption to an elution from
Doucil 50 (Fantes 1967). The specific activity was
, 106 unitsmg- l of protein. Mock IFN
preparations represent tissue culture supernatants
from cells treated with uninfected allantoic fluid in
place of NDV, which were carried through the same
procedure as the IFN-containing supernatants. The
units referred to are international units (the IFN
standard was obtained from National Institutes of
Health, Bethesda, MD, USA).
Animals
The strain of mice used here was the C3H strain
originally obtained from the National Institutes of
Health. At the beginning of the experiments the
animals had been through 31 crosses (brother-sister
matings) at the Theagenion Cancer Institute. A high
proportion ('80%) of these female mice normally
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develop mammary tumours during the first year of
age.
Handling and observation ofexperimental animals
IFN or mock IFN preparations in 0.1 ml of PBS
were injected i.p. while nursing or suckling (24 days)
with the doses and schedules indicated in the results
section. All adult mice were kept singly in cages,
except for the period of mating (3 days) or nursing
(24 days). From the fifth month of life to 1 year,
animals were examined for the appearance of
tumours every 2-3 days. The animals were
sacrificed 2 weeks after a tumour was first detected
and the tumours were weighed and examined
histologically.
Histology
The tumours were processed in the usual way by
formalin fixation and paraffin embedding and
virgin
(B-1-a)
(B-1-0)
OFFSPRING
C-1
sections of the tissue stained with hematoxylin and
eosin.
Results
Reduction in incidence ofmammary tumours in virgin
C3H mice given IFN while suckling
The effect of giving mouse IFN to nursing mothers
and suckling mice of C3H strain was examined
using the experimental plan outlined in Figure 1.
The development of tumours was followed by up to
1 year of life both in the mice receiving IFN, and
their progeny (see Methods). Several groups of
animals received IFN and were compared with their
control groups; the number of animals in each
group is listed in the first column of Table I. Group
A-1 received IFN only while nursing while group
A-2 received mock IFN (see Methods). All the
MOCK IFN (A-2)
I(B-2)
virgin
(B-2-a)
MOCK IFN
(B-1-y)
OFFSPRING
C-2
IFN MOCK IFN
(B-2-1) (B-2-y)
OFFSPRING OFFSPRING
C-3 C-4
Figure 1 Outline of experiment to test the effect of administration of mouse IFN during suckling and/or
lactation on the development of mammary tumours in C3H mice.INTERFERON AND MAMMARY TUMOURS IN C3H MICE 805
Table I Incidence of mammary tumours in female C3H
mice from Experiment I
Animals Average
Total showing % Animals weight of
Group and' number tumours with tumour
treatment animals by 1 year tumours (g)
Group A
A-i IFNb
While nursing 31 26 83.8 1.3
A-2 Mock IFN
While nursing 20 17 85.0 1.1
Group B
B-i IFNb
While suckling:
a stayed virgin 18 9 50.0 1.1
,B pregnant-IFNb
while nursing 16 13 81.2 1.4
y pregnant-mock
IFN while nursing 17 15 88.2 1.0
B-2 Mock IFN
While suckling:
a stayed virgin 16 14 87.5 1.5
,B pregnant-IFNb
while nursing 17 16 94.1 1.4
y pregnant-mock
IFN while nursing 15 13 86.6 1.0
Group C
C-1 52 40 76.9 1.3
C-2 virgin 42 31 74.8 1.4
C-3 73 58 79.4 1.4
C-4 52 41 78.8 1.6
aSee outline for first Experiment in Figure 1.
blO4 units per dose in 0.1ml given every 60-72h for 24
days.
animals in group B were from mothers in group A-
1, but some subgroups of B also received IFN
themselves, while suckling, (group B-1), while
nursing (B-2-/) or during both these periods (B-1-fl).
Because pregnancy is known to have a stimulatory
effect on the development of mammary tumours in
other strains of mice (Marchand, 1961), virgin
animals in the B group (B-1-a and B-2-cx) were
compared to others which were allowed to breed,
with or without subsequent administration of IFN
during lactation (groups B-1-f and y and B-2-f and
y). The progeny from animals in group B (the C
series) were untreated but followed for tumour
development. The numbers of animals developing
tumours within their first year of life are shown in
Table I for the various treatment groups.
While all the mice in group B were nursed by
mothers receiving IFN, only one half of the group
B mice received IFN directly by injection, while
they were suckling (group B-1). Of these, only those
which did not go on to pregnancy and lactation
showed a lower tumour incidence. The difference
was statistically significant (P<0.05). A comparison
of the incidence of tumours in the mice in groups
B-1-ax and B-2-a shows a protective effect of
administering IFN to suckling mice, so long as the
mice remain virgin. Mice similarly treated with IFN
while suckling and allowed to go on to breed (B-i-fl
and y) show no decrease in tumour incidence.
Lack of effect of IFN given during lactation on
tumour incidence
In the experiment outlined in Figure I there are 3
sets of treatment groups where the effect of giving
IFN while nursing can be assessed (A-i/A-2, B-1-
fl/B-1-y and B-2-fl/fl-2-y). In no case was there any
observed reduction in the incidence of tumours in
the mice receiving IFN as compared to the
respective control group, even when IFN had also
been administered to the mice while suckling (B-1-
fi). The stimulatory effect of pregnancy and
lactation on mammary tumour development
apparently is strong enough to overcome the
inhibitory effect of IFN administered during the
establishment phase of MMTV infection (i.e.
suckling). Another point to note is that there is
apparently not enough IFN transmitted to the
offspring from mothers receiving IFN to exert a
protective effect similar to that produced by IFN
administered directly, otherwise the mice in group
B-2-a, C1 and C3 should have shown a reduced
incidence of tumours.
In the above experiment, the same dose of IFN
(104 units per mouse) was used for suckling and
lactating mice so that effectively a higher dose was
administered to the smaller newborn mice than to
the adults. It was conceivable therefore, that a
higher dose of IFN given during lactation might
have some effect on tumour development. A second
experiment was performed to test this point and
also to confirm the observation that IFN
administered to suckling mice reduced the incidence
of mammary tumours in animals which did not
breed. Mice receiving IFN while suckling again
received 104 units per mouse (Group A). Two
groups of adult mice were given 104 and 105 units
of IFN, respectively, during lactation (Group B).
The results shown in Table II are very clear.
Increasing the dose of IFN for lactating mice has
no effect on tumour development. However, again,
suckling mice receiving IFN which remained virgin
showed a dramatic decrease in tumour incidence
(P<0.05). Only 39.2% developed tumours as
compared to 72% in the control group. As in the
first experiment, mice which went on to pregnancy
and lactation were not protected by IFN given to
them while newborn and suckling.806 T.R. TOLIOU et al.
Table II Development of tumours in female C3H mice
from second Experiment
Number
animals Average
Total showing % Animals weight of
number tumours developing tumours
Treatmenta animals by 1 year tumours (g)
Group A
Newborn given
while suckling:
IFN 104 units
virgin 28 11 39.2 1.0
1 pregnancy 24 21 87.5 1.2
IFN Mock
virgin 18 13 72.2 1.3
1 pregnancy 26 22 84.6 1.0
Group B
Adults given
while nursing:
IFN 104 units 21 19 90.4 1.1
IFN 105 units 21 20 95.2 1.0
Mock IFN=
104 units 20 17 85.0 1.1
Mock IFN=
105 units 19 15 78.9 1.2
aSee Figure 2.
bInterferon (or mock interferon) was administered in
0.1 ml every 48h for 24 days.
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Kinetics oftumour development
The data presented in Tables I and II refer only to
the number of tumours developing by 1 year. A
more complete picture can be obtained by following
the incidence of tumours at various time intervals
up to this point. In this way any delay in tumour
development produced by IFN treatment would be
detected. Complete data on the rate of tumour
development was available, since mice were
examined every 2-3 days for the appearance of
tumours and were autopsied 2 weeks after detection
(see Methods). However, even when the rate of
development of tumours was examined in this way,
no effect of IFN given during lactation could be
detected. Figure 2A shows the time course of
tumour development in the mice in groups B-la
and B-2a and clearly illustrates the protective effect
of IFN given during suckling on female mice
remaining virgin. Figure 2B shows similar curves
for similar groups of mice from Experiment 2. The
time course of tumour development in breeding
mice receiving IFN while suckling and subsequently
during lactation is also presented for both
experiments in Figure 2. These curves demonstrate
(a) the lack of effect of IFN given to lactating mice,
and (b) the antagonistic effect of subsequent
pregnancy on the protective effect of IFN given
during suckling.
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Figure 2 Development of tumours in groups of mice from A. Experiment I (a) and Experiment 11 (b). The
abscissa represents the age of the animals at the time when tumours were first detected. (0 *) Virgin
animals given IFN while suckling. (0 O) Virgin animals given mock IFN while suckling. (A A)
Breeding animals given IFN while suckling and subsequently during lactation.
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Size oftumours
In order to test for a possible effect of IFN on the
size of tumours developing, they were weighed at
autopsy and the average weight for each group was
determined. Tables I and II list the average tumour
weights for the different groups in Experiments I
and II and shows that in no case did IFN
treatment affect the size of tumours developing
subsequently. In histological examination the
tumours showed the characteristic pattern of mouse
mammary adenocarcinoma types A or B.
Discussion
In the experiments described here, we have asked
whether it was possible to affect the development of
spontaneous mammary tumours in C3H mice by
administering IFN only during those periods
known to be critical for infection with and
proliferation of MMTV. Both the weight of
tumours developing and the time of their
appearance were followed for the first year of life of
the mice in each group. In two separate
experiments, the same result was obtained; IFN
administered to suckling mice produced a
significant delay in the appearance of mammary
tumours, provided the mice remained virgin. The
protective effect if IFN was lost if the mice were
allowed to breed, even if IFN was also given during
lactation. Moreover, IFN treatment had no effect
on the size and histology of tumours if these
appeared, even in the virgin mice treated with IFN
while suckling.
These results are consistent with the idea that the
mouse IFN used here (produced in C243 cells)
could inhibit some event(s) in the initial infection of
newborn mice with MMTV from the milk.
However, there appeared to be no significant effect
on the hormonal-induced multiplication of MMTV
occurring at lactation, since neither lactating mice
nor their offspring were protected by IFN received
during lactation. Moreover, the stimulation to
MMTV replication and spread given by pregnancy
and lactation was sufficient to overcome the
protective effect of IFN given during suckling.
The authors are grateful to Mrs. A. Eukarpidou for
preparation and assay of the mouse interferon, and to
Professor I. Papapanagiotou and A. Granitsas for advice.
This paper represents part of a thesis (T.R.T.) presented at
the Medical School of the University of Thessaloniki,
Greece.
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